In agreement with this, a systematic review of 12 studies conducted in HR+, HER2‐negative metastatic breast cancer reported worse prognosis in patients whose cancers had PIK3CA mutations compared with wild‐type when treated with non‐PI3K inhibitors. This evidence concerns the gene ERBB2 and cancer.